Research and Development Focused on Health, Safety and Taste
First written in FY2016. 20 of 28 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「• Joint research projects with universities and research institutions: 3 per year – 6 • Peer-reviewed papers on health functionality: 3 per year – 8 papers」
The results for the fiscal year ending April 2026 included 6 joint research projects with universities and research institutions and 8 peer-reviewed papers on health functionality. Research and development expenses also increased to ¥2,418 million, with progress in research and academic presentations on well-being and physiological responses to flavor. - 2026-06-01AdvancedEarnings presentation
「Contributing to well-being and expanding demand for green tea and matcha through research and communications / mental and psychological health value, etc. / social health value, etc.」
The R&D description expanded beyond physical health value to include research into mental and psychological health value and social health value. - FY2026-H1RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥1,198 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses were disclosed as ¥1,198 million, while it was expressly stated that there were no material changes in the status of research and development activities. - FY2025-H1RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥1,114 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses were ¥1,114 million, while it was expressly stated that there were no material changes in the status of research and development activities. - FY2024-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥1,031 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses were disclosed as ¥1,031 million, while the status of research and development activities was stated to be unchanged. - FY2024-Q1RestatedAnnual report
「The Group's total research and development expenses for the three months ended June 30 were ¥577 million. There were no material changes in the status of the Group's research and development activities during the three months ended June 30.」
Research and development expenses were disclosed as ¥577 million, while the status of research and development activities was stated to be unchanged. - FY2023RestatedAnnual report
「In our research and development, we are pursuing basic and applied research with particular emphasis on health, safety and taste, as well as the environment as a contribution to a sustainable society. Through various tests, we validate the usefulness of the products we provide for maintaining people's health and continue to communicate the latest information.」
The focus of research and development has expanded from health, safety and taste to include the environment, while validation of health benefits through testing continues. Research and development expenses were ¥2,133 million. - FY2023-Q3RestatedAnnual report
「The Group's total research and development expenses for the nine months ended December 31 were ¥1,635 million. There were no material changes in the status of the Group's research and development activities during the nine months ended December 31.」
Research and development expenses of ¥1,635 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2023-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥1,136 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses were ¥1,136 million, while the status of research and development activities was stated to be unchanged. - FY2022RestatedAnnual report
「Among our product development concepts, we are pursuing basic and applied research with particular emphasis on health, safety and taste. Through various tests, we validate the usefulness of the products we provide for maintaining people's health and continue to communicate the latest information.」
The policy of emphasizing health, safety and taste, validating health benefits and developing Foods with Function Claims continues. - FY2022-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥889 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses of ¥889 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2021AdvancedAnnual report
「At the Central Research Institute, we are conducting joint research with universities and other research institutions to validate the effects of tea components, including the prevention of lifestyle-related diseases and improvements in cognitive function. We are also conducting research and development on the use of unused resources such as spent tea leaves, promoting the development of paper and resin products that utilize tea's functions. In addition, we scientifically established the compatibility of tea with food and used the findings in academic papers, conference presentations and promotional materials.」
Joint research with universities and other institutions continued, while research into tea and food compatibility progressed through paper submissions, academic presentations and use in promotional materials. Research and development expenses were ¥1,694 million. - FY2021-Q3AdvancedAnnual report
「In December, we began selling Oi Ocha Matcha, Japan's first Food with Function Claim product whose function of improving the accuracy of cognitive function, including attention and judgment, is attributed to the effects of theanine and tea catechins. The product uses our proprietary contract-grown matcha and brings out matcha's rich umami.」
Oi Ocha Matcha, a Food with Function Claim product addressing cognitive function, was launched in December using contract-grown matcha. Research and development expenses were ¥1,273 million. - FY2020AdvancedAnnual report
「At the Central Research Institute, we are conducting joint research with universities and other research institutions to validate the effects of tea components, including the prevention of lifestyle-related diseases and improvements in cognitive function. We also established the compatibility of tea with food and used the findings in academic presentations and promotional materials.」
The disclosure describes continued joint research with universities and other institutions, as well as research into the compatibility of tea with food and its use in academic presentations and promotional materials. - FY2020-Q3RestatedAnnual report
「The Group's total research and development expenses for the nine months ended December 31 were ¥1,392 million. There were no material changes in the status of the Group's research and development activities during the nine months ended December 31.」
Research and development expenses of ¥1,392 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2020-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥884 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses of ¥884 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2020-Q1RestatedAnnual report
「The Group's total research and development expenses for the three months ended June 30 were ¥446 million. There were no material changes in the status of the Group's research and development activities during the three months ended June 30.」
Research and development expenses of ¥446 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2019AdvancedAnnual report
「At the Central Research Institute, we are conducting joint research with universities and other research institutions to validate the effects of tea components, including the prevention of lifestyle-related diseases and improvements in cognitive function. We also established that green tea enhances the umami of Japanese cuisine and presented the findings at the National Council for Japanese Food Culture.」
The disclosure reports research results showing that green tea enhances the umami of Japanese cuisine, in addition to ongoing joint research with universities and other institutions. Research and development expenses were ¥1,833 million. - FY2019-Q3RestatedAnnual report
「The Group's total research and development expenses for the nine months ended December 31 were ¥1,367 million. There were no material changes in the status of the Group's research and development activities during the nine months ended December 31.」
Research and development expenses of ¥1,367 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2019-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥865 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses of ¥865 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2019-Q1RestatedAnnual report
「The Group's total research and development expenses for the three months ended June 30 were ¥462 million. There were no material changes in the status of the Group's research and development activities during the three months ended June 30.」
Research and development expenses of ¥462 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenses for the nine months ended December 31 were ¥1,330 million. There were no material changes in the status of the Group's research and development activities during the nine months ended December 31.」
Research and development expenses of ¥1,330 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenses for the six months ended September 30 were ¥879 million. There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
Research and development expenses of ¥879 million were recorded, while the status of research and development activities was stated to be unchanged. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the first three months of the fiscal year were ¥460 million. There were no material changes in the status of the Group's research and development activities during the period.」
Research and development expenses were ¥460 million, while the status of R&D activities was stated to have remained materially unchanged. - FY2017AdvancedAnnual report
「At the Central Research Institute, we are conducting joint research with social research institutions to validate the effects of tea components, including the prevention of lifestyle-related diseases and improvements in cognitive function. We also confirmed improved bowel regularity from consuming carrot purée, a key ingredient in vegetable beverages.」
The disclosure reports a specific research result: improved bowel regularity from consuming carrot purée, in addition to joint research with social research institutions. - FY2017-Q3RestatedAnnual report
「There were no material changes in the status of the Group's research and development activities during the nine months ended December 31.」
States that there were no material changes in research and development activities, indicating that the existing R&D policy continues. - FY2017-Q2RestatedAnnual report
「There were no material changes in the status of the Group's research and development activities during the six months ended September 30.」
The report states that there were no material changes in research and development activities, confirming the continuation of the existing policy. - FY2016First statedAnnual report
「In our research and development activities, we are pursuing basic and applied research with particular emphasis on “health,” “safety” and “taste,” among the elements of our basic philosophy.」
The policy is to enhance product quality and brand value through validation of health benefits, development of foods with function claims, and research into flavor and physical properties.